immunotherapy

Modulight Spotlights: LASER-SHARP RESEARCH – October 2025

This month we are highlighting exciting findings by S. Takao et al. from Hisataka Kobayashi’s lab at the National Cancer Institute, NIH. Published in Cancer Letters, the study shows that near-infrared photoimmunotherapy can destroy cancer cells by targeting intercellular adhesion molecule-1.

Modulight Spotlights: LASER-SHARP RESEARCH – October 2025 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – September 2025

Published in journal Cancer Medicine, the study shows that the therapeutic effect of photoimmunotherapy is highly dependent on the used light irradiation conditions. Application of the ML7710 medical laser at different durations and powers resulted in highest anti-tumor effect with increased light dose but lowering fluence rate below what is currently used in clinic.

Modulight Spotlights: LASER-SHARP RESEARCH – September 2025 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – August 2025

Laser-sharp research of the month is by Furusawa et al. at Center for Cancer Research, National Cancer Institute, USA. The discovery, published in Annals of Medicine, showed the potential of photoimmunotherapy for treating breast cancer. To expand the usefulness of photoimmunotherapy outside the clinically approved head & neck indication, the new therapy targeted epithelial cell adhesion molecule in breast cancer.

Modulight Spotlights: LASER-SHARP RESEARCH – August 2025 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – March 2025

Coleman et al. / MSKCC developed a vascular-targeted therapy for bladder cancer. Padeliporfin is illuminated with the Modulight’s ML7710 laser, resulting in selective ablation of bladder tumors, without harming the healthy bladder tissue.

Modulight Spotlights: LASER-SHARP RESEARCH – March 2025 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – February 2025

A. Lepland and the teams at University of Tartu, Estonia and Veneto Institute of Oncology, Italy, developed a new immunotherapy for triple negative breast cancer, using Modulight ML6000-series laser. Tumor growth slowed down and the cancer’s spreading to the lungs was suppressed.

Modulight Spotlights: LASER-SHARP RESEARCH – February 2025 Read More »

Peptide-Drug Conjugate for Therapeutic Reprogramming of Tumor-Associated Macrophages in Breast Cancer

Published in: Advanced Science Authors: Anni Lepland, Elisa Peranzoni, Uku Haljasorg, Eliana K. Asciutto, Maria Crespí-Amer, Lorenzo Modesti, Kalle Kilk, Manuel Lombardia, Gerardo Acosta, Miriam Royo, Pärt Peterson, Ilaria Marigo, Tambet Teesalu, Pablo Scodeller  

Peptide-Drug Conjugate for Therapeutic Reprogramming of Tumor-Associated Macrophages in Breast Cancer Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – January 2025

Kobayashi et al. at NIH developed a therapy which results in tumor cell membrane destruction and immunogenic cell death. When activated with the ML7710 laser, there was proven efficacy against various cancer cell types including pancreatic, oral, breast, and ovarian cancer.

Modulight Spotlights: LASER-SHARP RESEARCH – January 2025 Read More »

Comparative study of immune response to local tumor destruction modalities in a murine breast cancer model

Published in: Frontiers in Oncology Authors: Sadna Budhu, Kwanghee Kim, Wesley Yip, Stephen La Rosa, Sylvia Jebiwott, Liqun Cai, Aliya Holland, Jasmine Thomas, Dina Preise, Alex Somma, Benjamin Gordon, Avigdor Scherz, Jedd D. Wolchok, Joseph Erinjeri, Taha Merghoub, Jonathan A. Coleman  

Comparative study of immune response to local tumor destruction modalities in a murine breast cancer model Read More »

Scroll to Top